Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride (KCl) provides potassium ions, essential for maintaining intracellular fluid volume, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose 5% provides water and calories for energy, correcting fluid deficits and dehydration. Sodium chloride 0.3% provides sodium and chloride ions to maintain extracellular fluid osmolarity and volume. The combination corrects electrolyte imbalances and provides maintenance fluids.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion, rate determined by potassium deficit and serum potassium monitoring; typical maintenance: 20-40 mEq potassium per day in divided doses; maximum infusion rate: 10 mEq/h; maximum concentration: 40 mEq/L via peripheral line.
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium does not have a classic terminal half-life as it is an electrolyte; its clearance depends on body distribution and renal function. In patients with normal renal function, the elimination half-life for an administered dose is approximately 3–6 hours, reflecting distribution into intracellular space and subsequent renal excretion.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: ~90% of potassium is excreted by the kidneys, primarily via distal tubular secretion under aldosterone regulation; ~10% is lost in feces via colonic secretion. Biliary excretion is negligible. In this formulation, dextrose and sodium chloride are also excreted renally.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."